Ultima Genomics is a transformative life sciences company dedicated to driving the scale of genomic information to advance biology and human health. By developing a novel, foundational approach to sequencing at scale, the company is successfully lowering the cost of genomic data, thereby unlocking new possibilities for clinical diagnostics and basic research.
Backed by approximately $600 million in funding from prominent global investors, Ultima Genomics operates at the cutting edge of science and technology. The company brings together a multidisciplinary team of experts—including visionary entrepreneurs, pioneering scientists, and elite hardware and software engineers—all united by the goal of making high-throughput sequencing a ubiquitous tool in healthcare and research.